Intercept Pharmaceuticals

$35.47
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.18 (-0.50%) Today
$0.00 (0.00%) As of 8:00 AM EST after-hours

Why Robinhood?

You can buy or sell ICPT and other stocks, options, and ETFs commission-free!

About ICPT

Intercept Pharmaceuticals, Inc. Common Stock, also called Intercept Pharmaceuticals, is a biopharmaceutical company, which engages in the research, development, and commercialization of novel therapeutics in treating chronic liver diseases. Its product pipeline is OCALIVA which is used for the treatment of primary biliary cholangitis, nonalcoholic steatohepatitis, primary sclerosing cholangitis, and biliary atresia. The company was founded by Mark E. Pruzanski and Roberto Pellicciari on September 4, 2002 and is headquartered in New York, NY. The listed name for ICPT is Intercept Pharmaceuticals, Inc. Common Stock.

CEO
Mark E. Pruzanski
Employees
583
Headquarters
New York, New York
Founded
2002
Market Cap
1.17B
Price-Earnings Ratio
Dividend Yield
Average Volume
1.18M
High Today
$36.69
Low Today
$35.38
Open Price
$35.98
Volume
595.30K
52 Week High
$125.00
52 Week Low
$27.02

Collections

ICPT Earnings

-$3.03
-$2.56
-$2.08
-$1.61
Q1 FY19
Q2 FY19
Q3 FY19
Q4 FY19
Q1 FY20
Q2 FY20
Q3 FY20
Estimated
-$1.93 per share
Actual
-$1.61 per share

You May Also Like